Induced pluripotent stem cell–based Drug Repurposing for Amyotrophic lateral sclerosis Medicine (iDReAM) study: protocol for a phase I dose escalation study of bosutinib for amyotrophic lateral sclerosis patients

Keiko Imamura, Yuishin Izumi, Haruhiko Banno, Ryuji Uozumi, Satoshi Morita, Naohiro Egawa, Takashi Ayaki, Makiko Nagai, Kazutoshi Nishiyama, Yasuhiro Watanabe, Ritsuko Hanajima, Ryosuke Oki, Koji Fujita, Naoto Takahashi, Takaaki Ikeda, Akira Shimizu, Akiko Morinaga, Tomoko Hirohashi, Yosuke Fujii, Ryosuke Takahashi, Haruhisa Inoue

ABSTRACT

Introduction Amyotrophic lateral sclerosis (ALS) is a progressive and severe neurodegenerative disease caused by motor neuron death. There have as yet been no fundamental curative medicines, and the development of a medicine for ALS is urgently required. Induced pluripotent stem cell (iPSC)-based drug repurposing identified an Src/c-Abi inhibitor, bosutinib, as a candidate molecular targeted therapy for ALS. The objectives of this study are to evaluate the safety and tolerability of bosutinib for the treatment of patients with ALS and to explore the efficacy of bosutinib on ALS. This study is the first clinical trial of administered bosutinib for patients with ALS.

Methods and analysis An open-label, multicentre phase I dose escalation study has been designed. The study consists of a 12-week observation period, a 1-week transitional period, a 12-week study treatment period and a 4-week follow-up period. After completion of the transitional period, subjects whose total ALS Functional Rating Scale–Revised (ALSFRS-R) score decreased by 1–3 points during the 12-week observation period receive bosutinib for 12 weeks. Three to six patients with ALS are enrolled in each of the four bosutinib dose levels (100, 200, 300 or 400 mg/day) to evaluate the safety and tolerability under a 3+3 dose escalation study design. Dose escalation and maximum tolerated dose are determined by the safety assessment committee comprising oncologists/haematologists and neurologists based on the incidence of dose-limiting toxicity in the first 4 weeks of the treatment at each dose level. A recommended phase II dose is determined by the safety assessment committee on completion of the 12-week study treatment in all subjects at all dose levels. The efficacy of bosutinib is also evaluated exploratorily using ALS clinical scores and biomarkers.

Ethics and dissemination This study received full ethical approval from the institutional review board of each participating site. The findings of the study will be disseminated in peer-reviewed journals and at scientific conferences.

Strengths and limitations of this study

- This is the first study to use an Src/c-Abi inhibitor, bosutinib, for patients with amyotrophic lateral sclerosis (ALS), and is considered to be the first step in the development of a molecular-targeted therapy for ALS.
- This study presents a novel type of protocol design by combining the safety study of oncology and the efficacy study of neurology.
- Limitations are the open-label and single-arm designs for safety and tolerability.

INTRODUCTION

Amyotrophic lateral sclerosis (ALS) is an intractable neurodegenerative disease caused by the death of motor neurons resulting in progressive skeletal muscle weakness. The worldwide incidence of ALS is approximately 2 per 100 000 persons per year.1 About 10% of patients with ALS have familial inheritance, and in Japan, around 30% of those patients have SOD1 gene mutation.2 Although the disease mechanism of ALS is still unknown, motor neuron death and accumulation of misfolded proteins are essential pathological characteristics of the disease. In the late stage of the disease, patients lose their spontaneous motor function and present...
respiratory failure. The survival period is within 3–5 years after onset if a mechanical ventilator is not adopted.4 To date, riluzole5 and edaravone6 have been approved for ALS treatment, although there are no fundamental curative medicines.

We previously identified bosutinib, an Src/c-Abl inhibitor, as resulting in an increase in the survival rate of ALS motor neurons derived from familial ALS with SOD1 mutation and from sporadic ALS patients’ induced pluripotent stem cells (iPSCs). Bosutinib improved the impaired autophagy, reduced the accumulation of misfolded proteins and attenuated the energy shortage of ALS patient motor neurons.7 Furthermore, treatment with bosutinib attenuated the ALS-related phenotypes of ALS model mice.7,8 Penetration of the blood–brain barrier was confirmed by a previous report.9 Based on these findings, we hypothesised that bosutinib, as a molecular targeted therapy, would attenuate the progression of muscle weakness and elongate the survival period of patients with ALS according to its pathomechanism-dependent effects, and thus we designed the clinical trial of bosutinib for patients with ALS.

Bosutinib is a selective inhibitor of Src/c-Abl tyrosine kinase, approved for the treatment of chronic myelogenous leukaemia (CML). In September 2012, the US Food and Drug Administration (FDA) approved bosutinib for the treatment of CML, chronic, accelerated or blast phase Philadelphia chromosome-positive CML, for those who are resistant to or who cannot tolerate other therapies including imatinib. Then, FDA granted accelerated approval of bosutinib for the treatment of patients with newly diagnosed CML in December 2017. Although known frequent adverse effects include diarrhoea, thrombocytopenia and liver transaminase elevations,10 from the results of past clinical trials with patients with CML, it became clear that the safety of bosutinib can be managed. However, because the disease-related physical conditions of patients with ALS are different from those of patients with CML, evaluation of the safety and tolerability of bosutinib in patients with ALS was planned to be conducted in the present study. Also, evaluation of the efficacy of bosutinib in patients with ALS using ALS Functional Rating Scale-Revised (ALSFRS-R)11 and biomarkers was designed to be conducted in an exploratory manner.

METHODS

Study design

This study is an investigator-initiated, open-label, multicentre, phase I dose escalation study to evaluate the safety and tolerability of bosutinib for determination of the maximum tolerated dose (MTD) and a recommended phase II dose (RP2D) in patients with ALS. Efficacy is also evaluated exploratorily.

The following patients will be included in this study.

► Patients with sporadic ALS diagnosed with isolated definite, probable or probable-laboratory supported ALS as determined by the Updated Awaji Criteria,12 or patients diagnosed with ALS with progressive muscle weakness and a superoxide dismutase 1 (SOD1) mutation (which has already been reported).

► Patients with Grade 1 or 2 ALS according to ALS severity classification as determined by the Japanese Ministry of Health, Labour and Welfare (MHLW) Specific Disease Research Group in Japan (box 1); patients with Grade 3 ALS with a SOD1 mutation are allowed to be enrolled.

► Patients with ALS within 2 years after onset at the time of primary enrolment (patients with ALS with an SOD1 mutation within 5 years after the onset are allowed to be enrolled).

► Patients with total ALSFRS-R score reduced by 1–3 points during the observation period.

Box 1 Criteria for severity of amyotrophic lateral sclerosis (ALS) (Ministry of Health and Welfare Study Group on Neurodegenerative Diseases as Specified Diseases, 1998)

► Grade 1: Able to work or perform housework; movement disturbance of one limb or dysarthria caused by bulbar palsy.

► Grade 2: Independent living but inconveniences in daily life; movement disorders of one or two limbs, trunk, tongue, face, palate, larynx.

► Grade 3: Requiring assistance for eating, excretion or ambulation; three or more muscle weaknesses in limbs, trunk, tongue, face, palate and larynx.

► Grade 4: Need assistance in everyday life; presence of respiratory insufficiency, difficulty in coughing out sputum or dysphagia.

► Grade 5: Bedridden and full life support equipment required.

(Source: FDA edaravone medical review /MCI186-19-Protocol, Section 16.1.1, p250/267)

ALSFRS-R, ALS Functional Rating Scale-Revised.
Box 2  Eligibility criteria

Inclusion criteria:
1. Evidence of a personally signed and dated informed consent document indicating that the patient has been informed of all pertinent aspects of the study. To be additionally signed by a delegate signer if the subject is unable to handwrite.
2. Patients aged ≥20 years and <80 years at the time of informed consent.
3. Patients with positive already-reported SOD1 gene mutation and progressive muscle weakness; patients with sporadic ALS who are categorised as either ‘Definite ALS’ or ‘Probable ALS’ or ‘Probable-laboratory supported ALS’ in the Updated Awaji Criteria for the diagnosis of ALS.
4. Patients at Grade 1 or 2 in the Japan ALS Severity Scale of the grant-in-aid programme for chronic diseases from the Japanese Ministry of Health, Labour and Welfare; patients with positive SOD1 mutation of Grade 1, 2 or 3.
5. Patients with ALS that occurred within 2 years at the time of the first registration; patients with positive SOD1 mutation within 5 years after disease onset.
6. Patients who can visit hospitals regularly as outpatients.
7. Patients with change in total ALSFRS-R score during the observation period from −1 to −3 points.
8. Urine pregnancy test (for female of childbearing potential) negative at screening.
9. Male and female patients of childbearing potential must agree to use one highly effective method of contraception as outlined in this protocol for the duration of the study and for at least 28 days after the last dose of investigational product.
10. Uncontrolled hypomagnesaemia or uncorrected hypokalaemia due to potential effects on the QT interval.
11. Uncontrolled angina or hypertension within 3 months prior to registration.
12. Myocardial infarction within 12 months prior to registration.
13. Clinical significant ventricular arrhythmia (such as ventricular tachycardia, ventricular fibrillation or Torsades de pointes).
14. Diagnosed or suspected congenital or acquired prolonged QT interval or QTc (QTcF should not exceed 500 ms).
15. Unexplained syncope.
16. Clinical significant or uncontrolled hypokalaemia due to potential effects on the QT interval.
17. Pregnant female patients; breastfeeding female patients; fertile male and female patients of childbearing potential who are unwilling or unable to use one highly effective method of contraception as outlined in this protocol for the duration of the study and for at least 28 days after the last dose of the investigational product.
18. History of clinically significant or uncontrolled cardiac disease including:
   - History of, or active, congestive heart failure.
   - Uncontrolled angina or hypertension within 3 months prior to registration.
   - Myocardial infarction within 12 months prior to registration.
   - Clinically significant ventricular arrhythmia (such as ventricular tachycardia, ventricular fibrillation or Torsades de pointes).
   - Diagnosed or suspected congenital or acquired prolonged QT interval or QTc (QTcF should not exceed 500 ms).
   - Unexplained syncope.
19. Other important medical conditions, including:
   - History of, or active, malignancy within 5 years prior to registration.
   - Patients who have undergone a cardiotomy procedure.
   - Patients with chronic obstructive pulmonary disease.

Exclusion criteria:
1. Patients with tracheostomy.
2. Patients who have used non-invasive ventilation due to ALS symptoms.
3. Patients whose % Forced vital capacity (FVC) is less than 70% at the time of first and second registrations.
4. Patients who have nerve conduction study findings of demyelination such as conduction block.
5. Patients who are taking edaravone; patients who started riluzole or edaravone after start of the observation period; patients who changed the dosage of riluzole after start of the observation period.
6. Patients with bulbar type ALS with dysphagia and dysarthria.
7. Patients with cognitive impairment.
8. Pregnant female patients; breastfeeding female patients; fertile male and female patients of childbearing potential who are unwilling or unable to use one highly effective method of contraception as outlined in this protocol for the duration of the study and for at least 28 days after the last dose of the investigational product.
9. History of clinically significant or uncontrolled cardiac disease including:
   - History of, or active, congestive heart failure.
   - Uncontrolled angina or hypertension within 3 months prior to registration.
   - Myocardial infarction within 12 months prior to registration.
   - Clinically significant ventricular arrhythmia (such as ventricular tachycardia, ventricular fibrillation or Torsades de pointes).
   - Diagnosed or suspected congenital or acquired prolonged QT interval or QTc (QTcF should not exceed 500 ms).
   - Unexplained syncope.
10. Uncontrolled hypomagnesaemia or uncorrected hypokalaemia due to potential effects on the QT interval.
11. Patient who is taking the following medicines during study drugs administration:
   - Combination of warfarin anticoagulation or related oral anticoagulation. Combination of therapeutic anticoagulant therapy with low molecular weight heparin is acceptable.
   - Src or c-Abl inhibitors.
   - Other treatments for cancer.
   - Drugs known to prolong the QT interval or predispose to Torsades de Pointes.
   - Drugs affecting gastric pH such as proton pump inhibitors (eg, lansoprazole).
12. History of malignancy within 5 years prior to registration with the exception of basal cell carcinoma or cervical carcinoma in situ or stage 1 or 2 cancer that is considered adequately treated and currently in complete remission for at least 12 months.
13. Patients who were enrolled in other clinical study within 12 weeks before the first registration or are expected to be enrolled in other clinical study using a study drug during this study.
14. Known prior or suspected severe hypersensitivity to study drugs or any component in their formulations.
15. Patients with active, uncontrolled bacterial, fungal or viral infection, including hepatitis B virus, hepatitis C virus, known HIV or AIDS-related illness.
16. Recent or ongoing clinically significant GI disorder (eg, Crohn’s disease, ulcerative colitis, or prior total or partial gastrectomy).
17. Patients with chronic obstructive pulmonary disease.
Box 2 Continued

18. Major surgery or radiotherapy within 14 days prior to registration at the time of the first registration.
19. Patient who fulfills the conditions:
   a. Neutrophil count (ANC)<1500/mm³ or white cell count <3000/mm³ at the time of the first and second registrations.
   b. Haemoglobin<9.0 g/dL at the time of the first and second registrations.
   c. Platelet count <100,000/L at the time of the first and second registrations.
20. Other acute or chronic medical or psychiatric condition including recent (within the past year) or active suicidal ideation or behaviour or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgement of the investigator, would make the participant inappropriate for entry into this study.
21. Investigation site staff members directly involved in the conduct of the study and their family members, site staff members otherwise supervised by the investigator (subinvestigator), including their family members.

ALS, amyotrophic lateral sclerosis; ALSFRS-R, ALS Functional Rating Scale-Revised; GI, gastrointestinal.

Figure 1 Study schedule of the iDReAM (Induced pluripotent stem cell–based Drug Repurposing for Amyotrophic lateral sclerosis Medicine) study.

Figure 2 3+3 dose escalation study design in the iDReAM (Induced pluripotent stem cell–based Drug Repurposing for Amyotrophic lateral sclerosis Medicine) study. DLT, dose-limiting toxicity.

and will be projected as a recommended clinical dose for patients with ALS. Thus, in order to confirm its suitability for long-term clinical administration, RP2D will be selected comprehensively based on the evaluation of all safety data obtained (including DLT, dose intensity and other relevant data throughout the treatment period), as well as pharmacological data, exploratory endpoints and other relevant data.

The target sample size of this clinical trial is 12–24 subjects. The number of subjects at each dose level of this study will depend on the results of the DLT assessments.

Box 3 Definition of DLT

- Grade 4 neutropenia (<500/mm³) persisting for >7 day duration or Grade 4 white cell count decrease for >7 day duration (<1000/mm³).
- Febrile neutropenia (ANC<1000/mm³ and fever ≥38.5°C).
- Grade 4 thrombocytopenia >48 hour duration or with bleeding requiring platelet transfusion.
- Any Grade 3 or 4 clinically evident non-haematological toxicity – except for ≥Grade 3 nausea, vomiting or diarrhoea unless subject is on optimal medical therapy, or – electrolyte abnormality requiring hospitalisation, or is life-threatening.
- ≥66% of bosutinib doses that cannot be completed due to an adverse event related to the investigational drug (during the first 4 weeks of treatment and the entire 12 weeks of treatment).
- An event otherwise determined as a DLT by principal (sub) investigator and the safety assessment committee.
- Any clinically significant ≥Grade 2 toxicity that requires >14 days to resolve (to ≤Grade 1 despite optimal medical therapy).

Remarks: Respiratory failure is a very important clinical event for amyotrophic lateral sclerosis (ALS). Thus, dyspnoea, hypoxia, pneumonitis, pulmonary oedema and pulmonary fibrosis according to CTCAE V.4.03 will be considered as ‘clinically relevant ≥Grade 2 adverse events.’ Toxicity of bosutinib in patients with ALS is not known. Dose-limiting toxicity (DLT) criteria may be modified or added if it is considered necessary to include additional DLT criteria deemed appropriate for patients with ALS based on information accumulated from this study.
Outcomes
The primary endpoint is DLT during the first 4 weeks of treatment with bosutinib, and during the study treatment period (12 weeks). Adverse events, abnormal laboratory test results, vital signs (blood pressure, pulse rate, body temperature), ECG and chest X-ray findings are evaluated as secondary endpoints. Adverse events are graded based on the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) V.4.03. Pharmacokinetic assessments will be conducted for subjects who have serious adverse events. Changes in ALS clinical score including total ALSFRS-R score and in the grade of the Japan ALS severity classification, and changes from the baseline of %FVC and grip power are evaluated as exploratory endpoints. Changes in blood neurofilament L (NF-L) and phosphorylated neurofilament H (pNF-H) during the observation period and the study treatment period are also evaluated as exploratory endpoints.

Data analysis and statistical method
The frequency of DLT during the study treatment period will be analysed for each dose level. The frequencies of adverse events during the study treatment period are analysed for each dose group. Onset timing, severity and the relationship of the study drug to adverse events are summarised. The respective correlations of changes in total ALSFRS-R score versus blood NF-L and blood pNF-H will be assessed.

Patient and public involvement
Patients and the public were not involved in the design of this study.

Registration
This study has been planning since March 2019 to March 2021, and participating four sites in Japan.

DISCUSSION
This study evaluates the safety and tolerability of bosutinib for the molecularly targeted treatment of patients with ALS as well as explores the efficacy of bosutinib on ALS. The potential efficacy of bosutinib for patients with ALS has already been identified by an approach applying iPSC-based drug repurposing. We previously developed a phenotypic screen system to evaluate compounds with a readout of motor neuron survival using ALS patient-iPSCs with SOD1 mutations. Application of the screen revealed that bosutinib increased the survival rate of ALS motor neurons. This drug was also effective for sporadic ALS patients-iPSC models. Thus, we designed the clinical trial for ALS patients with SOD1 mutation and for patients with sporadic ALS, with the expectation that bosutinib will become a candidate molecularly targeted drug for ALS.

Bosutinib is a therapeutic agent used for the treatment of patients with CML, and the accumulated data of previous clinical trials presenting the safety of bosutinib can also be managed in patients with CML. However, evaluation of the safety and tolerability of bosutinib in patients with ALS is required in order to support the development of bosutinib for the treatment of ALS. This clinical trial was designed as a ‘triple 3 design’ by a combination of the safety study, the 3+3 dose escalation study design of oncology and the efficacy study, with a 3-month observation period for uniform subject inclusion, of neurology.

Safety information has been accumulated from clinical studies of bosutinib in patients with CML. Known frequent adverse effects of bosutinib include diarrhoea (70%), thrombocytopenia (55%) and liver enzyme abnormalities (alanine aminotransferase increase of 31%, aspartate aminotransferase increase of 23%) according to the Bosutinib Trial in First-Line Chronic Myelogenous Leukemia Treatment (BFORE) trial, which demonstrated the efficacy of bosutinib as first-line treatment in adult patients with newly diagnosed chronic-phase CML. While diarrhoea is the most commonly reported adverse event, it is generally manageable by dietary advice to avoid dairy products, high fat content and spicy food before anti-diarrhoeal agents. Patients with haematological adverse events or liver transaminase elevations are managed by dose interruption or reduction. The occurrence and management of adverse events in patients with ALS seem to be comparable to those with CML. While referring to the accumulated clinical data of CML, this study was designed to evaluate any unacceptable adverse events that specifically occur in patients with ALS, as well as the treatment tolerability in patients with ALS. Given that a 4-week DLT evaluation period was included in the phase I/II study to determine MTD in patients with CML (NCT00811070), a 4-week DLT evaluation period is included in this study to determine MTD with bosutinib in patients with ALS. In addition to MTD, this study determines RP2D considered optimal for patients with ALS. After discussion with the regulatory authority referencing the clinical data of CML, 12 weeks of the study treatment period is considered necessary to determine RP2D in the current study. Regarding the dose, a 400 mg dose of bosutinib has been approved by FDA as a first-line treatment for CML. For the non-oncology study of bosutinib, a phase 2 study has been conducted in patients with autosomal dominant polycystic kidney disease, in which bosutinib at starting doses of 200 and 400 mg/day was administered. Thus, up to 400 mg of bosutinib dose was selected for evaluation of the safety and tolerability for patients with ALS in this study. Regarding the drug interaction, CYP3A inhibitors/inducers are prohibited because bosutinib is primarily metabolised by CYP3A. Drugs affecting gastric pH are also prohibited because blood concentration of bosutinib may be decreased, resulting in reduced efficacy.

Patients with ALS eventually develop degeneration of both upper and lower motor neurons, but their symptoms and disease processes vary. In the early stage of the disease, only upper or lower motor neuron signs may manifest themselves. Some patients also continue to exhibit either one of the motor neuron signs for relatively
long periods of time. Especially, ALS patients with an SOD1 mutation often do not meet typical ALS diagnostic criteria because they lack upper motor neuron signs, and they sometimes present a different clinical prognosis from sporadic ALS,\(^6\) showing slow progression in some cases. Thus, inclusion criteria contained special provisions for ALS patients with an SOD1 mutation.

The variety of clinical symptoms and disease progression speed among patients is one of the reasons that cause difficulty for clinical trial evaluation. In the current study, an observation period of 12 weeks was established to enable the evaluation of ALS patients with uniform progression speed, the same as in previous clinical trials with edaravone, which was approved for ALS to cause a delay in motor function decline.\(^6\) To explore the efficacy of bosutinib, a change in ALS clinical score such as the ALSFRS-R score, the grade in Japan ALS severity classification of bosutinib, a change in ALS clinical score such as the spinal fluid of patients with ALS,\(^17\)–\(^19\) are also evaluated to see if they sometimes present a different clinical prognosis from sporadic ALS,\(^6\) because they lack upper motor neuron signs, and SOD1 mutation often do not meet typical ALS diagnostic criteria because they lack upper motor neuron signs, and they sometimes present a different clinical prognosis from sporadic ALS,\(^6\) showing slow progression in some cases. Thus, inclusion criteria contained special provisions for ALS patients with an SOD1 mutation.

This study is the first to use an Src/c-Abl inhibitor, bosutinib, for patients with ALS, and it presents a novel type of protocol design by combining a safety study for oncology and an efficacy study for neurology. This is a phase I study for the safety and tolerability evaluation, and the number of subjects was limited. Therefore, it will be necessary to conduct further safety and efficacy evaluations in the following phases. This study is considered to be the first step in the development of a molecularly targeted drug for ALS therapy.

**Ethics and dissemination**

This study was approved by the Institutional Review Boards of Kyoto University, Tokushima University, Kitasato University and Tottori University. This study was registered with the University Hospital Medical Information Network clinical trials registry (UMIN) Clinical Trials Registry (UMIN000036295) and the Japan Medical Association Center for Clinical Trials (JMACCT CTR) (JMA-IIA00419).

**Author affiliations**

1 Center for IPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan
2 Department of Neurology, Kitasato University Graduate School of Biomedical Sciences, Tokushima, Japan
3 Department of Biomedical Statistics and Bioinformatics, Kyoto University, Kyoto, Japan
4 Department of Neurology, Graduate School of Medicine, Kyoto University, Kyoto, Japan
5 Department of Neurology, Kitasato University School of Medicine, Sagamihara, Japan
6 Division of Neurology, Department of Brain and Neurosciences, Faculty of Medicine, Tottori University, Yonago, Japan
7 Department of Hematology, Nephrology, and Rheumatology, Akita University Graduate School of Medicine, Akita, Japan
8 Institute for Advancement of Clinical and Translational Science (IACIT), Kyoto University Hospital, Kyoto, Japan
9 Pfizer R&D Japan G.K, Tokyo, Japan

**Twitter** Takafumi Ikeda @takafumios

**Acknowledgements** We appreciate the advice on the protocol from Manabu Muto, Toshiyuki Kitano, Hirofumi Maruyama, Satoshi Kaneko, and Mitsuwsaza Watanabe, and the protocol review and study preparation from Pfizer Japan and its global medicine team of bosutinib. We would like to express our sincere gratitude to all our coworkers and collaborators, to Atsushi Onodera and Satoshi Nishihama for making the contracts, to Nozomi Kawabata, Mikie Iijima and Azusa Okayama for their administrative support, and to Peter Karagiannis for critical reading.

**Contributors** KI, AM, TH, YF and HI made contributions to the conception and design of the study protocol. RU and SM provided statistical expertise. YI, HB, NE, TA, MN, KN, YW, RH, RD, KF, NT, TI, AS and RT made clinical suggestions for the design of the protocol.

**Funding** This research was funded in part by a grant for Clinical Research and Trials for the Clinical Innovation Network (CIN) and Realization of Regenerative Medicine from the Japan Agency for Medical Research and Development (AMED) (19ek0201053h0002), and the Research Project for Practical Applications of Regenerative Medicine (18bk0104019h0001) from AMED to HI.

**Competing interests** The study drug bosutinib and the pharmacokinetic analysis for only subject-experienced serious adverse events are supported by Pfizer JAPAN under the Clinical Research Collaboration Agreement. RT and NT received research funding and honoraria for lectures from Pfizer.

**Patient consent for publication** Not required.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Data availability statement** Data are available in a public, open access repository.

**Open access** This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) licence, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

**ORCID iDs**

Ryujirou Usui http://orcid.org/0000-0002-9546-9869
Haruhisa Inoue http://orcid.org/0000-0003-4736-9537

**REFERENCES**

1 Marin B, Boumèdiene F, Logroscino G, et al. Variation in worldwide incidence of amyotrophic lateral sclerosis: a meta-analysis. *Int J Epidemiol* 2017;46:57–74.

2 Nakamura R, Sone J, Atsuta N, et al. Next-Generation sequencing of 28 ALS-related genes in a Japanese ALS cohort. *Neurobiol Aging* 2016;39:219.e1–219.e8.

3 Finsterer J, Burgunder J-M. Recent progress in the genetics of motor neuron disease. *Eur J Med Genet* 2014;57:103–12.

4 Maurel C, Dangoumau A, Marouillat S, et al. Causative genes in amyotrophic lateral sclerosis and protein degradation pathways: a link to neurodegeneration. *Mol Neurobiol* 2018;55:480–99.

5 Bennetsemin G, Lacomblez L, Meininger V, et al. A controlled trial of riluzole in amyotrophic lateral sclerosis. *ALS/Riluzole Study Group*. *N Engl J Med* 1994;330:585–91.

6 Abe K, Aoki M, Tsuji S, et al. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. *The Lancet Neurology* 2017;16:505–12.

7 Imamura K, Izumi Y, Watanabe A, et al. The Src/c-Abl pathway is a potential therapeutic target in amyotrophic lateral sclerosis. *Sci Transl Med* 2017;9, doi:10.1126/scitranslmed.aaf3962.

8 Wengiang C, Lonskaya I, Hebron ML, et al. Parkin-Mediated reduction of nuclear and soluble TDP-43 reverses behavioral decline in symptomatic mice. *Hum Mol Genet* 2014;23:4960–9.

9 Lonskaya I, Hebron ML, Destorges NM, et al. Tyrosine kinase inhibition increases functional parkin–Beclin-1 interaction and enhances amyloid clearance and cognitive performance. *EMBO Mol Med* 2013;5:1247–62.

Imamura K, et al. *BMJ Open* 2019;9:e033131. doi:10.1136/bmjopen-2019-033131
10 Cortes JE, Apperley JF, DeAngelo DJ, et al. Management of adverse events associated with bosutinib treatment of chronic-phase chronic myeloid leukemia: expert panel review. *J Hematol Oncol* 2018;11.

11 Cedarbaum JM, Stambler N, Malta E, et al. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (phase III). *J Neurol Sci* 1999;169:13–21.

12 Costa J, Swash M, de Carvalho M, et al. Awaji criteria for the diagnosis of amyotrophic lateral sclerosis: a systematic review. *Arch Neurol* 2012;69:1410–6.

13 Jaki T, Clive S, Weir CJ. Principles of dose finding studies in cancer: a comparison of trial designs. *Cancer Chemother Pharmacol* 2013;71:1107–14.

14 Tesar V, Ciechanowski K, Pei Y, et al. Bosutinib versus placebo for autosomal dominant polycystic kidney disease. *J Am Soc Nephrol* 2017;28:3404–13.

15 Nishiyama A, Niihori T, Warita H, et al. Comprehensive targeted next-generation sequencing in Japanese familial amyotrophic lateral sclerosis. *Neurobiol Aging* 2017;53:194.e1–194.e8.

16 Bali T, Self W, Liu J, et al. Defining SOD1 ALS natural history to guide therapeutic clinical trial design. *J Neurol Neurosurg Psychiatry* 2017;88:99–105.

17 De Schaepdryver M, Jeromin A, Gille B, et al. Comparison of elevated phosphorylated neurofilament heavy chains in serum and cerebrospinal fluid of patients with amyotrophic lateral sclerosis. *J Neurol Neurosurg Psychiatry* 2018;89:367–73.

18 Verde F, Steinacker P, Weishaupt JH, et al. Neurofilament light chain in serum for the diagnosis of amyotrophic lateral sclerosis. *J Neurol Neurosurg Psychiatry* 2019;90:157–64.

19 Poesen K, Van Damme P. Diagnostic and prognostic performance of neurofilaments in ALS. *Front Neurol* 2018;9:1167.